Type 2 Diabetes Trial, Not Yet Recruiting NCT07376226 Sponsor: Harvard School of Public Health (HSPH) Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Not Yet Recruiting

NCT07376226
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 or older
  • People who have been diagnosed with type 2 diabetes
  • People whose HbA1c (a blood test that shows average blood sugar levels over the past few months) is between 6.5% and 12.0%
  • People whose fasting C-peptide level (a blood test that shows whether the pancreas is still producing insulin) is 0.5 ng/ml or above, measured at the screening visit

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who are currently using insulin
  • People who have a form of diabetes other than typical type 2, such as latent autoimmune diabetes in adults (LADA) or a genetic form called maturity-onset diabetes of the young (MODY)
  • People whose kidneys are not functioning well enough, based on a blood test called eGFR falling below a certain level (confirm with trial site)
  • People who have had a heart attack in the past 6 months, or who have severe or unstable heart failure
  • People who are currently taking weight loss medication, including a class of diabetes or weight loss injections such as semaglutide or dulaglutide
  • People who have had a change in the dose of a long-term medication that could affect the study results within the past 3 months
  • People with significantly abnormal results on routine blood tests, such as unusual haemoglobin levels
  • People with serious digestive conditions, a history of major stomach or bowel surgery, or gallstones
  • People with serious disease affecting the heart, blood vessels, kidneys, liver, lungs, adrenal glands, or nervous system, where participation could raise safety concerns or affect study results
  • People who have had cancer (other than a common type of skin cancer called non-melanoma skin cancer) within the past 5 years
  • People who have lost or gained more than 5 pounds — or more than 2% of their body weight if they weigh over 250 pounds — in the past 2 months
  • People who are pregnant, planning to become pregnant within the next 6 months, or currently breastfeeding
  • People with a serious psychiatric condition that could affect their ability to take part in the study
  • People who are unable to eat the meals provided as part of the study, for example due to food allergies
  • People whose lifestyle or personal circumstances may make it difficult to follow the study's dietary plan
  • People who are unable to have an MRI scan, for example due to claustrophobia, metal implants in the body, or body size (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 10 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Courtney M Peterson, Harvard School of Public Health (HSPH)

Phone: 617-998-6333

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Harvard School of Public Health (HSPH)
Registry
ClinicalTrials.gov
Start date
1 September 2026
Est. completion
1 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Mean 24-hour Glucose Levels; Mean 3-hour Glucose Levels; Mean 3-hour Insulin; Mean 3-hour C-Peptide; Insulin Sensitivity; Dynamic Beta-Cell Responsivity; Static Beta-Cell Responsivity; Glycemic Variability; Time-in-range Metrics from CGM

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 10 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov